1Sajatovic, M, Strejilevich, SA, Gildengers, AG, Dols, A, Al Jurdi, RK, Forester, BP, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord 2015; 17: 689–704.
2Crump, C, Sundquist, K, Winkleby, MA, Sundquist, J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013; 70: 931–9.10.1001/jamapsychiatry.2013.1394
3Tsai, SY, Lee, CH, Kuo, CJ, Chen, CC. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry 2005; 66: 1586–91.10.4088/JCP.v66n1215
4Correll, CU, Detraux, J, De Lepeleire, J, De Hert, M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14: 119–36.10.1002/wps.20204
5Lan, CC, Liu, CC, Lin, CH, Lan, TY, McInnis, MG, Chan, CH, et al. A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study. Bipolar Disord 2015; 17: 705–14.10.1111/bdi.12336
6Prosser, JM, Fieve, RR. Patients receiving lithium therapy have a reduced prevalence of neurological and cardiovascular disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016; 71: 39–44.
7Olesen, JB, Abildstrom, SZ, Erdal, J, Gislason, GH, Weeke, P, Andersson, C, et al. Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. Pharmacoepidemiol Drug Saf 2011; 20: 964–71.10.1002/pds.2073
8Chuang, YC, Chuang, HY, Lin, TK, Chang, CC, Lu, CH, Chang, WN, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012; 53: 120–8.
9WHO. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death (9th revision) (ICD-9). World Health Organization, 1977.
10Wu, CS, Wang, SC, Gau, SS, Tsai, HJ, Cheng, YC. Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 2013; 73: 414–21.
11WHO Collaborating Centre for Drug Statistic Methodology. ATC Index with DDDs. World Health Organization, 2009.
12Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
13Chen, WY, Chen, LY, Liu, HC, Wu, CS, Yang, SY, Pan, CH, et al. Antipsychotic medications and stroke in schizophrenia: a case-crossover study. PLoS One 2017; 12: e0179424.
14Hu, HH, Sheng, WY, Chu, FL, Lan, CF, Chiang, BN. Incidence of stroke in Taiwan. Stroke 1992; 23: 1237–41.10.1161/01.STR.23.9.1237
15Lopinto-Khoury, C, Mintzer, S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol 2010; 12: 300–8.
16Lorenz, MW, Polak, JF, Kavousi, M, Mathiesen, EB, Volzke, H, Tuomainen, TP, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053–62.
17Miao, Y, Liao, JK. Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother 2014; 14: 173–85.
18Chen, HF, Xu, LP, Luo, ZY, Yu, ZQ, Li, ZY, Cui, QY, et al. Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review. Drug Des Devel Ther 2013; 7: 767–70.10.2147/DDDT.S47718
19Nanau, RM, Neuman, MG. Adverse drug reactions induced by valproic acid. Clin Biochem 2013; 46: 1323–38.10.1016/j.clinbiochem.2013.06.012
20Choi, SE, Jang, HJ, Kang, Y, Jung, JG, Han, SJ, Kim, HJ, et al. Atherosclerosis induced by a high-fat diet is alleviated by lithium chloride via reduction of VCAM expression in ApoE-deficient mice. Vascul Pharmacol 2010; 53: 264–72.10.1016/j.vph.2010.09.004
21Wang, Z, Zhang, X, Chen, S, Wang, D, Wu, J, Liang, T, et al. Lithium chloride inhibits vascular smooth muscle cell proliferation and migration and alleviates injury-induced neointimal hyperplasia via induction of PGC-1alpha. PLoS One 2013; 8: e55471.
22Sacchetti, E, Trifiro, G, Caputi, A, Turrina, C, Spina, E, Cricelli, C, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008; 22: 39–46.
23Zornberg, GL, Jick, H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219–23.10.1016/S0140-6736(00)02784-7
24Janicak, PG. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 1993; 54(Suppl): 35–41; discussion 55–6.
25Fiedorowicz, JG, Solomon, DA, Endicott, J, Leon, AC, Li, C, Rice, JP, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med 2009; 71: 598–606.10.1097/PSY.0b013e3181acee26
26Chen, PH, Chang, CK, Chiang, SJ, Lin, YK, Tsai, SY, Huang, SH. Diabetes mellitus and first episode mania associated with cardiovascular diseases in patients with older-age bipolar disorder. Psychiatry Res 2017; 249: 65–9.
27Ward, MC, White, DT, Druss, BG. A meta-review of lifestyle interventions for cardiovascular risk factors in the general medical population: lessons for individuals with serious mental illness. J Clin Psychiatry 2015; 76: e477–86.